{"id":59852,"date":"2024-08-15T13:04:19","date_gmt":"2024-08-15T11:04:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/"},"modified":"2024-08-15T13:04:19","modified_gmt":"2024-08-15T11:04:19","slug":"aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/","title":{"rendered":"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma"},"content":{"rendered":"
\n

HAYWARD, Calif.–(BUSINESS WIRE)–#biotechnology<\/a>—Aarvik Therapeutics<\/a>, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc.<\/a> has exercised the option to exclusively license the collaboration program.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAs part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has been responsible for discovery and preclinical development of a novel ADC molecule that relies on the unique modular platform developed by Aarvik. ArriVent will be responsible for clinical development and commercialization. Aarvik has received an upfront payment, research funding and an opt-in payment, and is eligible to receive contingent development and commercial milestones, plus royalties.<\/p>\n

\n\u201cAarvik has shown that it can combine the most advanced protein engineering technologies with deep ADC drug development expertise to enable next-generation, best-in-class oncology therapies,\u201d said Jagath Reddy Junutula<\/a>, PhD, Co-founder, President and CEO of Aarvik Therapeutics. \u201cAarvik will continue to pursue previously hard-to-treat indications through the power of its novel multi-targeting platforms.\u201d<\/p>\n

\n\u201cWe are delighted to see Aarvik reach this significant milestone,\u201d said Sachdev Sidhu, PhD, Co-founder and Board member of Aarvik Therapeutics. \u201cThis provides further validation and underscores the power and potential of Aarvik antibody platforms and deep protein engineering capabilities.\u201d<\/p>\n

\nAbout Aarvik Therapeutics<\/b><\/p>\n

\nAarvik Therapeutics combines unique, proprietary modular platforms with multiple target mechanisms to develop novel molecules with an improved therapeutic index for oncology targets. Backed by the extensive scientific, research, development and business expertise of its founders, Board, SAB and team members, Aarvik Therapeutics is applying its vision and passion to create transformational benefit for cancer patients.<\/p>\n

\nFor additional information, visit www.aarviktx.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact
\n
Pradeep Fernandes
\n
contact@aarviktx.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HAYWARD, Calif.–(BUSINESS WIRE)–#biotechnology—Aarvik Therapeutics, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59852","6":"format-standard","7":"category-industry"},"yoast_head":"\nAarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HAYWARD, Calif.–(BUSINESS WIRE)–#biotechnology—Aarvik Therapeutics, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-15T11:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240815164343\/en\/2214979\/22\/aarvik.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma\",\"datePublished\":\"2024-08-15T11:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/\"},\"wordCount\":289,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240815164343\\\/en\\\/2214979\\\/22\\\/aarvik.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/\",\"name\":\"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240815164343\\\/en\\\/2214979\\\/22\\\/aarvik.jpg\",\"datePublished\":\"2024-08-15T11:04:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240815164343\\\/en\\\/2214979\\\/22\\\/aarvik.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240815164343\\\/en\\\/2214979\\\/22\\\/aarvik.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/","og_locale":"en_US","og_type":"article","og_title":"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Pharma Trend","og_description":"HAYWARD, Calif.–(BUSINESS WIRE)–#biotechnology—Aarvik Therapeutics, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/","og_site_name":"Pharma Trend","article_published_time":"2024-08-15T11:04:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240815164343\/en\/2214979\/22\/aarvik.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma","datePublished":"2024-08-15T11:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/"},"wordCount":289,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240815164343\/en\/2214979\/22\/aarvik.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/","url":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/","name":"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240815164343\/en\/2214979\/22\/aarvik.jpg","datePublished":"2024-08-15T11:04:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240815164343\/en\/2214979\/22\/aarvik.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240815164343\/en\/2214979\/22\/aarvik.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aarvik-therapeutics-announces-option-exercise-by-collaboration-partner-arrivent-biopharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59852"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59852\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}